Joint Formulary & PAD

Candesartan cilexetil - Hypertension

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important
Preferred
Preferred angiotensin II receptor blocker

PAD Profile

ChemicalSubstance :
Candesartan cilexetil
Indication :
Hypertension
Group Name :
Keywords :
ARBs, high blood pressure, raised blood pressure
Brand Names Include :
Amias
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Other Indications

Below are listed other indications that Candesartan cilexetil is used to treat.

Committee Recommendations (2)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the 1st line use of Angiotensin Receptor Blockers (ARBs) instead of an Angiotensin Converting Enzyme (ACE) inhibitor, for adults with hypertension where the use of an ARB or ACE is deemed equally appropriate.

Losartan or candesartan - 1st line

Alternative options:
Irebsartan - Green
Telmisartan - Green
Valsartan - Green
Olmesartan - Green

Azlisartan - do not initiate in new patients
Eprosartan - do not initiate in new patients

Local hypertension guidelines / pathways will be reviewed and updated in light of this decision

GENERIC candesartan has been considered by the PCN and has been assigned a GREEN traffic light status.

NOTE - the branded product, Amias, was considered BLACK at the PCN in May 2017.